Extended endocrine therapy use and decision making after breast cancer diagnosis
Nearly 40% of women with stage I breast cancer and two-thirds with stage II decided to extend endocrine therapy. Decision making was influenced by patient values and varied little by stage. These results can inform physician-patient discussion about extending endocrine therapy.
Authors
- Lauren P. Wallner (ORCID: https://orcid.org/0000-0002-1279-8617)
- Paul Abrahamse (ORCID: https://orcid.org/0000-0001-7433-153X)
- Steven J. Katz (ORCID: https://orcid.org/0000-0002-1151-861X)
- Allison Furgal (ORCID: https://orcid.org/0000-0001-8081-2444)
- Timothy P. Hofer (ORCID: https://orcid.org/0000-0003-0434-8787)
- Sarah T. Hawley (ORCID: https://orcid.org/0000-0001-5756-645X)
- Kevin R. Ward (ORCID: https://orcid.org/0000-0001-5939-409X)
- Archana Radhakrishnan (ORCID: https://orcid.org/0000-0001-7689-6390)
- Allison W. Kurian (ORCID: https://orcid.org/0000-0002-6175-9470)
- Christine M. Veenstra (ORCID: https://orcid.org/0000-0001-9947-7156)
- Ann S. Hamilton (ORCID: https://orcid.org/0000-0001-5898-2308)
Institutions
- Los Angeles County Department of Public Health (US)
- Emory University (US)
- University of Michigan (US)
- VA Ann Arbor Healthcare System (US)
- Stanford Health Care (US)
- Michigan United (US)
- Michigan Medicine (US)
- VA Center for Clinical Management Research (US)
- Stanford Medicine (US)
- Department of Health Services (US)
- Stanford University (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1093/jnci/djaf076
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87